Passage Bio (NASDAQ:PASG) reported its full-year 2025 financial results on Tuesday, detailing a leaner operational structure and significant enrollment momentum for its lead gene therapy candidate in frontotemporal dementia.
Amylyx Pharmaceuticals (NASDAQ:AMLX) reported a significantly narrowed net loss for 2025 on Tuesday, as the company aggressively cut costs following its retreat from the ALS market and redirected capital toward its metabolic disease pipeline.
Prime Medicine (NASDAQ:PRME) reported full-year 2025 financial results on Tuesday, signaling a strategic shift toward commercial-stage readiness as its "search-and-replace" gene editing platform achieves its first human clinical validations.
CalciMedica (NASDAQ:CALC) reported its full-year 2025 financial results on Tuesday, outlining a path forward for its lead candidate, Auxora™, despite the recent discontinuation of its primary kidney injury study.
SOPHiA GENETICS (NASDAQ:SOPH) reported a strong finish to its fiscal year on Tuesday, pairing double-digit revenue growth with significant margin expansion as the healthcare-tech firm moves closer to its goal of operational profitability.
Esperion Therapeutics (NASDAQ:ESPR) moved to significantly broaden its cardiovascular portfolio on Tuesday, announcing a deal to acquire privately held Corstasis Therapeutics and its first-of-its-kind nasal spray for heart failure-related edema.
Precision BioSciences (NASDAQ:DTIL) announced Monday that it has achieved a $7.5 million clinical milestone under its licensing agreement with TG Therapeutics (NASDAQ:TGTX).
Astrana Health (NASDAQ:ASTH) delivered a year of explosive scale in 2025, according to financial results released Monday, with total revenue reaching $3.18 billion.
Takeda (NYSE:TAK) and Protagonist Therapeutics (NASDAQ:PTGX) secured a major regulatory milestone on Monday as the U.S. Food and Drug Administration (FDA) granted Priority Review to rusfertide, an investigational treatment for polycythemia vera (PV).
Alaunos Therapeutics (NASDAQ:TCRT) released proof-of-concept data from two separate diet-induced obesity (DIO) mouse studies on Monday, marking a strategic pivot toward non-hormonal metabolic treatments.
Ocugen (NASDAQ:OCGN) announced Monday that it has completed patient enrollment for its pivotal Phase 3 liMeliGhT clinical trial, evaluating OCU400 for the treatment of retinitis pigmentosa (RP).
Pharvaris (NASDAQ:PHVS) dominated the clinical spotlight at the American Academy of Allergy, Asthma & Immunology (AAAAI) 2026 meeting on Monday, unveiling full data from its RAPIDe-3 and CHAPTER-1 trials.
